The investment 'will significantly increase the capacity of the manufacturing site' to meet the demand for 'innovative medicines', the company said.
The Danish company has found that its Semaglutide medication, originally meant for diabetes, is also effective against obesity, giving it massive global potential.
Goldman Sachs, a financial firm, predicted last month that the global market for anti-obesity medication (AOM) could grow to $100 billion (â¬91.5 billion) by 2030. It's currently valued at just under six billion (â¬5.5 billion).
[
add
]
[
|
|
...
]